Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

Core Insights - CytoMed Therapeutics Limited has successfully completed dose level 1 of its first-in-human Phase I dose-escalation clinical trial (ANGELICA Trial) for late-stage cancer patients and plans to start dose level 2 in Q3 2025 [1][2] - The ANGELICA Trial is focused on evaluating the safety and tolerability of allogeneic NKG2DL-targeting CAR gamma delta T cells (CTM-N2D) for various cancer indications, including advanced solid and hematological malignancies [2] - CTM-N2D utilizes gamma delta T cells from healthy donors, which can be infused into patients without the need for donor-patient compatibility matching, differentiating it from conventional CAR-αβ T cell therapies [3][4] Company Overview - CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR), focusing on developing novel cell-based allogeneic immunotherapies for cancer treatment [5] - The company aims to address the clinical limitations and commercial challenges of existing CAR-T therapies, particularly in treating solid tumors [5]